Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.
Grant MJ, Aredo JV, Starrett JH, Stockhammer P, van Alderwerelt van Rosenburgh IK, Wurtz A, Piper-Valillo AJ, Piotrowska Z, Falcon C, Yu HA, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li FY, Neal J, Lemmon MA, Walther Z, Politi K, Goldberg SB. Grant MJ, et al. Among authors: starrett jh. Clin Cancer Res. 2023 Jun 1;29(11):2123-2130. doi: 10.1158/1078-0432.CCR-22-3497. Clin Cancer Res. 2023. PMID: 36913537 Free PMC article.
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.
Truini A, Starrett JH, Stewart T, Ashtekar K, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. Truini A, et al. Among authors: starrett jh. Clin Cancer Res. 2019 Nov 1;25(21):6382-6391. doi: 10.1158/1078-0432.CCR-19-0780. Epub 2019 Jun 10. Clin Cancer Res. 2019. PMID: 31182434 Free PMC article.
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations.
Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech SM, Unni AM, Homer R, Lockwood WW, Michor F, Goldberg SB, Lemmon MA, Smith PD, Cross DAE, Politi K. Starrett JH, et al. Cancer Res. 2020 May 15;80(10):2017-2030. doi: 10.1158/0008-5472.CAN-19-3819. Epub 2020 Mar 19. Cancer Res. 2020. PMID: 32193290 Free PMC article.
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
Tu E, McGlinchey K, Wang J, Martin P, Ching SL, Floc'h N, Kurasawa J, Starrett JH, Lazdun Y, Wetzel L, Nuttall B, Ng FS, Coffman KT, Smith PD, Politi K, Cooper ZA, Streicher K. Tu E, et al. Among authors: starrett jh. JCI Insight. 2022 Feb 8;7(3):e142843. doi: 10.1172/jci.insight.142843. JCI Insight. 2022. PMID: 35132961 Free PMC article.
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Bartolacci C, et al. Nat Commun. 2022 Jul 26;13(1):4327. doi: 10.1038/s41467-022-31963-4. Nat Commun. 2022. PMID: 35882862 Free PMC article.
Author Correction: Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP. Bartolacci C, et al. Nat Commun. 2022 Aug 8;13(1):4640. doi: 10.1038/s41467-022-32459-x. Nat Commun. 2022. PMID: 35941179 Free PMC article. No abstract available.